Examining a new imaging method for gastrointestinal cancers
CLDN18.2 Targeted 68Ga-PMD22 PET Imaging in Patients With Gastrointestinal Tumours
This study is testing a new imaging method using a special tracer to see if it can help doctors better detect stomach and colon cancers in patients.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | N/A to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05937919 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of a novel tracer, 68Ga-PMD22, which targets the CLDN18.2 protein to detect its expression in patients with gastric and colorectal cancers. The tracer is administered via intravenous injection and is designed to improve imaging accuracy for these types of tumors. The study aims to explore the safety and imaging capabilities of this tracer through PET/CT scans in patients who are suspected of having cancer or are scheduled for tumor-related procedures. The research builds on previous findings that highlight the role of CLDN18.2 in tumor biology.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected gastric or colorectal cancer who are planning to undergo biopsy or surgical treatment within the next two months.
Not a fit: Patients with severe liver or kidney dysfunction, claustrophobia, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the detection and diagnosis of gastrointestinal cancers, leading to better-targeted treatments.
How similar studies have performed: Previous studies have shown promising results with similar imaging approaches targeting CLDN18.2, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * In the near future (within 2 months), patients who plan to undergo puncture biopsy or undergo tumor surgical treatment or are clinically highly suspected of cancer (including primary and tumor recurrence and metastasis) * Able to understand and voluntarily sign informed consent forms, with good compliance Exclusion Criteria: * Severe abnormalities in liver and kidney function * Suffering from claustrophobia or other mental illnesses * Pregnant and lactating women
Where this trial is running
Beijing
- Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Rongxi Wang
- Email: zhzwrx.123@163.com
- Phone: +8615584172170
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.